KRAS and non-small cell lung carcinoma: Lou et al. found upregulated YTHDF1 expression in KRAS and TP53 mutant NSCLC cell lines, which could promote Cyclin B1 Translation through m6A modulation and contribute to the poor prognosis of KRAS/TP53 co-mutation LUADs [23].